An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access
Authors
Keywords
-
Journal
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
Volume -, Issue 41, Pages e1-e12
Publisher
American Society of Clinical Oncology (ASCO)
Online
2021-05-07
DOI
10.1200/edbk_100028
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017
- (2021) Marc A. Rodwin et al. EUROPEAN JOURNAL OF CANCER
- Enhancing global access to cancer medicines
- (2020) Javier Cortes et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The cost of cancer in Europe 2018
- (2020) Thomas Hofmarcher et al. EUROPEAN JOURNAL OF CANCER
- Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis
- (2020) Kerstin N Vokinger et al. LANCET ONCOLOGY
- Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients
- (2020) Luciene Schluckebier et al. BMC CANCER
- Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
- (2020) David M. Waterhouse et al. JOURNAL OF CLINICAL ONCOLOGY
- Women Who Are Young, Non‐White , and with Lower Socioeconomic Status Report Higher Financial Toxicity up to 1 Year After Breast Cancer Surgery: A Mixed‐Effects Regression Analysis
- (2020) Mary C. Politi et al. ONCOLOGIST
- Choosing Wisely India: ten low-value or harmful practices that should be avoided in cancer care
- (2019) C S Pramesh et al. LANCET ONCOLOGY
- Efficacy and Safety of Ceritinib (450 mg/day or 600 mg/day) With Food vs 750 mg/day Fasted in Patients With ALK-Positive NSCLC: Primary Efficacy Results From ASCEND-8 Study
- (2019) Byoung Chul Cho et al. Journal of Thoracic Oncology
- The economic impact of the transition from branded to generic oncology drugs
- (2019) W. Y. Cheung et al. Current Oncology
- Financial toxicity in gynecologic oncology
- (2019) Sara Bouberhan et al. GYNECOLOGIC ONCOLOGY
- Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
- (2019) Caicun Zhou et al. Lancet Respiratory Medicine
- Potential Life‐Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada
- (2019) Joanna Gotfrit et al. ONCOLOGIST
- Value assessment of oncology drugs using a weighted criterion‐based approach
- (2019) Doreen A. Ezeife et al. CANCER
- Soaring Cost of Cancer Treatment: Moving Beyond Sticker Shock
- (2018) Cary P. Gross et al. JOURNAL OF CLINICAL ONCOLOGY
- Trajectories of Injectable Cancer Drug Costs After Launch in the United States
- (2018) Noa Gordon et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer groundshot: going global before going to the moon
- (2018) Bishal Gyawali et al. LANCET ONCOLOGY
- American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs
- (2018) Journal of Oncology Practice
- The Value of Biomarkers in Optimizing the Use of Immuno-oncologic Therapy
- (2018) Carlos G. Ferreira et al. CURRENT DRUG TARGETS
- Financial burden among lung cancer patients in a publically funded healthcare system
- (2018) Doreen A. Ezeife et al. Clinical Lung Cancer
- A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer
- (2017) Daniel A Goldstein et al. JNCI-Journal of the National Cancer Institute
- ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase ( ALK )-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
- (2017) Byoung Chul Cho et al. Journal of Thoracic Oncology
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks
- (2017) Joseph C Del Paggio et al. LANCET ONCOLOGY
- The high price of anticancer drugs: origins, implications, barriers, solutions
- (2017) Vinay Prasad et al. Nature Reviews Clinical Oncology
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Financial distress in patients with advanced cancer
- (2017) Cécile Barbaret et al. PLoS One
- A global comparison of the cost of patented cancer drugs in relation to global differences in wealth
- (2017) Daniel A. Goldstein et al. Oncotarget
- Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
- (2017) Vinay Prasad et al. JAMA Internal Medicine
- A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer
- (2017) Daniel A Goldstein et al. JNCI-Journal of the National Cancer Institute
- Personalized medicine for non-small cell lung cancer: where are we now and where can we go?
- (2017) Doreen A. Ezeife et al. Expert Review of Respiratory Medicine
- ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe
- (2016) N. Cherny et al. ANNALS OF ONCOLOGY
- A Roadmap and Cost Implications of Establishing Comprehensive Cancer Care Using a Teleradiotherapy Network in a Group of Sub-Saharan African Countries With No Access to Radiation Therapy
- (2016) Niloy R. Datta et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer
- (2016) Christopher S. Lathan et al. JOURNAL OF CLINICAL ONCOLOGY
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
- (2016) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
- (2016) Scott D. Ramsey et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
- (2016) Sabine Vogler et al. LANCET ONCOLOGY
- Actual costs of cancer drugs in 15 European countries
- (2016) Wim H van Harten et al. LANCET ONCOLOGY
- Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World
- (2016) D. A. Goldstein et al. ONCOLOGIST
- Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
- (2016) Andrew Hill et al. BMJ Open
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration
- (2015) Doreen A. Ezeife et al. CANCER
- Five Years of Cancer Drug Approvals
- (2015) Sham Mailankody et al. JAMA Oncology
- Drug shortages in European countries: a trade-off between market attractiveness and cost containment?
- (2014) Kim Pauwels et al. BMC HEALTH SERVICES RESEARCH
- The development of a financial toxicity patient-reported outcome in cancer: The COST measure
- (2014) Jonas A. de Souza et al. CANCER
- Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non–Small-Cell Lung Cancer: The Bar Is Dropping
- (2014) Adrian G. Sacher et al. JOURNAL OF CLINICAL ONCOLOGY
- Reporting and Grading Financial Toxicity
- (2014) Nandita Khera JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
- (2014) Lee M. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Delivery of affordable and equitable cancer care in India
- (2014) C S Pramesh et al. LANCET ONCOLOGY
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
- (2014) Tito Fojo et al. JAMA Otolaryngology-Head & Neck Surgery
- Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
- (2013) Stacie B. Dusetzina et al. JOURNAL OF CLINICAL ONCOLOGY
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)
- (2013) M. Neil Reaume et al. LUNG CANCER
- Cancer care challenges in developing countries
- (2011) Adi J. Price et al. CANCER
- Cost Effectiveness of Evidence-Based Treatment Guidelines for the Treatment of Non–Small-Cell Lung Cancer in the Community Setting
- (2010) Marcus A. Neubauer et al. Journal of Oncology Practice
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started